Company intelligence / Profile preview
TScan Therapeutics
Waltham, Massachusetts, United Statestscan.com ↗
- Ownership
- Public · TCRX
- Development stage
- Other
01
Overview
TScan is conducting clinical trials for both hematologic malignancies (ALLOHA Phase 1 trial) and solid tumors (PLEXI-T Phase 1 trial). Their lead candidates TSC-100 and TSC-101 are being developed to prevent relapse following allogeneic hematopoietic cell transplantation.
- Therapeutic areas
- OncologyHematology
- Modalities
- T cell receptor (TCR)-engineered T cell (TCR-T) therapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $11.5M
- Total revenue
- $10.3M
- Enterprise value
- $2.3M
Beyond the preview
Go deeper on TScan Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TScan Therapeutics.